Startups
NovAccel is a startup dedicated to the development of manufacturing technologies for medical radioactive isotopes, aiming to enable the practical application of next-generation cancer therapies such as Targeted Alpha Therapy (TAT).
TAT is a promising treatment modality that delivers highly potent alpha radiation emitted from drugs selectively accumulated in cancer cells, offering strong therapeutic efficacy. However, a global shortage of its key radioactive isotope, Actinium-225 (Ac-225), has become a major bottleneck to its widespread adoption.
NovAccel’s compact superconducting accelerator, designed at a scale of approximately 10 meters, combines small size with high efficiency, enabling a more stable and scalable supply of Ac-225 compared to conventional production methods.
Through this approach, NovAccel aims to establish a sustainable supply system that supports the entire value chain, from drug development to clinical application.
TAT is a promising treatment modality that delivers highly potent alpha radiation emitted from drugs selectively accumulated in cancer cells, offering strong therapeutic efficacy. However, a global shortage of its key radioactive isotope, Actinium-225 (Ac-225), has become a major bottleneck to its widespread adoption.
NovAccel’s compact superconducting accelerator, designed at a scale of approximately 10 meters, combines small size with high efficiency, enabling a more stable and scalable supply of Ac-225 compared to conventional production methods.
Through this approach, NovAccel aims to establish a sustainable supply system that supports the entire value chain, from drug development to clinical application.